Sonendo, Inc. (NYSE: SONX), a dental technology company and creator of the GentleWave System for less invasive and less painful root canal therapy, today announced its achievement of a new milestone of 800,000 GentleWave patient procedures. The achievement of this newest milestone demonstrates the confidence doctors and their patients have in the GentleWave System as an alternative to traditional root canal therapy, and the growing utilization and preference among customers for the GentleWave procedure. The milestone follows on the heels of the Company’s achievement of its 700,000 procedures milestone in late 2021.

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that in the context of the capital increase that was announced on 7 March 2022 and completed on 10 March 2022 by means of a private placement through an accelerated bookbuilding procedure, its share capital has increased from EUR 1,925,158.02 to EUR 2,460,486.98 and the number of issued and outstanding shares has increased from 18,579,260 to 23,746,528 ordinary shares, through the issuance of a total of 5,167,268 new shares.

Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2021 after the market close on Wednesday, March 23, 2022. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.

Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces it has received Medical Device Regulation (MDR) certification from its Notified Body, the British Standards Institution (BSI), ensuring continuous market access of the alfapump system in the European Union (EU).